Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation

Reporting of Amyloidosis Stem Cell Transplantation Outcomes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01606280

Enrollment

400

Registered

2012-05-25

Start date

2011-06-30

Completion date

2013-06-30

Last updated

2014-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloidosis

Keywords

Amyloidosis

Brief summary

This study examines the value of stem cell transplantation in managing light chain amyloidisis.

Detailed description

1. How does age at diagnosis affect prognosis in primary amyloidosis? 2. How do lab values at diagnosis such as Creatinine, AST/ALT, total serum protein, serum gamma globulin/immunoglobulin levels affect prognosis in primary amyloidosis? 3. How does degree of organ involvement/number of organs involved affect prognosis in primary amyloidosis? 4. How does initial treatment affect prognosis in primary amyloidosis? 4\. How do the specifics the stem cell transplant protocol affect prognosis in primary amyloidosis?

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Eligible for Stem cell transplantation less than age 75

Exclusion criteria

* Creatinine \> 3.0 * BNP \> 10000

Design outcomes

Primary

Measure	Time frame
Survival	up to 8 years

Countries

United States

Outcome results